Veru Inc (VERU) - Total Assets
Based on the latest financial reports, Veru Inc (VERU) holds total assets worth $47.57 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Veru Inc - Total Assets Trend (1990–2025)
This chart illustrates how Veru Inc's total assets have evolved over time, based on quarterly financial data. Also see VERU stock market capitalisation for the company's overall valuation and market capitalisation.
Veru Inc - Asset Composition Analysis
Current Asset Composition (September 2025)
Veru Inc's total assets of $47.57 Million consist of 63.4% current assets and 36.6% non-current assets. Review Veru Inc total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 52.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $6.88 Million | 23.1% |
Asset Composition Trend (1990–2025)
This chart illustrates how Veru Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See VERU stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Veru Inc's current assets represent 63.4% of total assets in 2025, a decrease from 78.3% in 1990.
- Cash Position: Cash and equivalents constituted 52.9% of total assets in 2025, up from 50.0% in 1990.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 23.0% of total assets, an increase from 0.0% in 1990.
- Asset Diversification: The largest asset category is goodwill at 23.1% of total assets.
Veru Inc Competitors by Total Assets
Key competitors of Veru Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Veru Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.16 | 2.97 | 2.79 |
| Quick Ratio | 5.16 | 2.62 | 2.40 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $29.68 Million | $23.36 Million | $30.50 Million |
Veru Inc - Advanced Valuation Insights
This section examines the relationship between Veru Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.00 |
| Latest Market Cap to Assets Ratio | 1.23 |
| Asset Growth Rate (YoY) | -50.6% |
| Total Assets | $29.84 Million |
| Market Capitalization | $36.76 Million USD |
Valuation Analysis
Above Book Valuation: The market values Veru Inc's assets above their book value (1.23x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Veru Inc's assets decreased by 50.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Veru Inc (1990–2025)
The table below shows the annual total assets of Veru Inc from 1990 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | $29.84 Million | -50.62% |
| 2024-09-30 | $60.42 Million | +20.78% |
| 2023-09-30 | $50.02 Million | -63.04% |
| 2022-09-30 | $135.36 Million | -24.02% |
| 2021-09-30 | $178.15 Million | +245.62% |
| 2020-09-30 | $51.54 Million | -3.89% |
| 2019-09-30 | $53.63 Million | +10.68% |
| 2018-09-30 | $48.45 Million | -12.39% |
| 2017-09-30 | $55.31 Million | +43.19% |
| 2016-09-30 | $38.62 Million | +3.07% |
| 2015-09-30 | $37.47 Million | +18.31% |
| 2014-09-30 | $31.67 Million | -9.94% |
| 2013-09-30 | $35.17 Million | +15.51% |
| 2012-09-30 | $30.45 Million | +56.59% |
| 2011-09-30 | $19.44 Million | +5.85% |
| 2010-09-30 | $18.37 Million | -0.93% |
| 2009-09-30 | $18.54 Million | +34.05% |
| 2008-09-30 | $13.83 Million | +23.56% |
| 2007-09-30 | $11.19 Million | +50.33% |
| 2006-09-30 | $7.45 Million | +31.11% |
| 2005-09-30 | $5.68 Million | +26.34% |
| 2004-09-30 | $4.50 Million | -10.73% |
| 2003-09-30 | $5.04 Million | -9.48% |
| 2002-09-30 | $5.56 Million | +28.45% |
| 2001-09-30 | $4.33 Million | +5.10% |
| 2000-09-30 | $4.12 Million | -36.67% |
| 1999-09-30 | $6.51 Million | -13.91% |
| 1998-09-30 | $7.56 Million | -9.36% |
| 1997-09-30 | $8.34 Million | -39.30% |
| 1996-09-30 | $13.74 Million | -0.45% |
| 1995-09-30 | $13.80 Million | -25.81% |
| 1994-09-30 | $18.60 Million | +84.16% |
| 1993-09-30 | $10.10 Million | 0.00% |
| 1992-09-30 | $10.10 Million | +23.17% |
| 1991-09-30 | $8.20 Million | -10.87% |
| 1990-09-30 | $9.20 Million | -- |
About Veru Inc
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosa… Read more